Men's Health

Not all men's health centers are the same, but they do have several qualities in common.

Men’s health clinics are becoming a place where men can come in and get all or most of their health care needs met in one visit. These clinics, the subject of a recent article in Urology Times, differ in design and layout but are the same in their focus on providing comprehensive health care for men. This slideshow offers a look at the Center for Reconstructive Urology and Men’s Health, University of Utah, Salt Lake City

Building fellowships in male andrology and broader men’s health is becoming a key role in training younger physicians in the field for men’s health clinics. These clinics, the subject of a recent article in Urology Times, differ in design and layout but are the same in their focus on providing comprehensive health care for men.

Urologists and internists who direct successful comprehensive men’s health centers in the U.S. say these centers need to do more than cater to men’s health needs. They should also cater to men’s wants. Specifically, here are three design elements you should incorporate into your men’s health center, if you haven’t done so already.

Multidisciplinary men’s health centers, rooted at hospitals, academic centers, and some private clinics, have expanded in the last few years and are meeting an important need in medicine, say key figures in these centers. Urologists are helping to drive these clinics’ success.

Men’s health clinics are a growing trend centered around the global care of men and the philosophy that men need to be taken care of in a holistic way. These clinics, the subject of a recent article in Urology Times, differ in design and layout but are the same in their focus on providing comphrensive health care for men.

Abiraterone acetate (ZYTIGA) as therapy for chemotherapy-naïve metastatic castration-resistant prostate cancer improved overall survival by a statistically significant 19% compared with placebo in the final analysis of the phase III COU-AA-302 clinical trial.

Take a tour of Iris Cantor Men’s Health Center at NewYork-Presbyterian/Weill Cornell with this slideshow.

The AUA’s Committee on Male Health has developed a checklist to serve as a resource of urologic and non-urologic men’s health considerations. Intended for urologists and other health care providers, it is also aimed at better coordinating care among men’s providers.

Drugs and devices in the pipeline from Repros Therapeutics, Bavarian Nordic, NxThera, Solace Therapeutics, Generex Biotechnology, Bioniche, OncoCyte, HistoSonics, and Pacific Edge.

Urology Times is committed to the men’s health trend and to helping you make the most of it, UT Group Content Director Richard R. Kerr writes.

The effect of the U.S. Preventive Services Task Force’s controversial grade “D” recommendation regarding PSA-based screening for prostate cancer “has been minimal at best,” according to a research letter that also shows a “shocking” level of statewide variance in screening, a leading prostate cancer expert said.

The ConfirmMDx for Prostate Cancer test qualifies for Medicare coverage effective Nov. 3, 2014, MDxHealth SA announced, while the maker of a second test, the Decipher Prostate Cancer Classifier, has added a new preferred provider organization to expand coverage of that test.

Results of a study analyzing data from the Surveillance, Epidemiology, and End Results program add to evidence of race-related disparity in receipt of treatment for prostate cancer, but show that having health insurance reduces the difference in care.

Results of a phase II study from the Prostate Cancer Clinical Trials Consortium show that abiraterone acetate (ZYTIGA) has modest clinical activity in men with progressive metastatic castrate-resistant prostate cancer previously treated with ketoconazole.

Inappropriate use of a gonadotropin-releasing hormone agonist for androgen deprivation therapy of localized prostate cancer fell dramatically following implementation of reimbursement cuts mandated by the Medicare Modernization Act of 2003, but overuse remains problematic, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.

In light the controversial studies linking testosterone replacement therapy to cardiovascular risks, three urologists discuss how their approach to prescribing TRT has (or hasn't) changed.

In this interview, Ian Thompson, MD, answers questions about the downside of diagnosing low-risk prostate cancer, the burdens of active surveillance and how to minimize them, and how his own approach to screening and biopsy have changed.

The Decipher Prostate Cancer Classifier test predicts disease aggressiveness, influences treatment decisions, and predicts which patients may benefit from post-prostatectomy radiation therapy, according to findings from three studies presented at the American Society for Radiation Oncology annual meeting in San Francisco.

An FDA advisory committee has voted to restrict indications for testosterone replacement therapy and require additional clinical trials to test the safety of the drugs, decisions that have drawn mixed reactions from urologists.

In this article, Ahmed A. Hussein, MD, and James F. Smith, MD, MS, examine the effect of malignancy and anti-cancer treatment on fertility, review current fertility preservation methods, and offer a preview of fertility preservation techniques that hold future promise.

The FDA’s approval of enzalutamide (XTANDI) to treat metastatic castration-resistant prostate cancer (CRPC) in the pre-chemotherapy setting is a potential game changer for both patients and treating physicians, especially urologists, according to leaders in the prostate cancer field.

Physical activity lowers men’s risk of developing nocturia and should be recommended to patients with the condition, a leading men’s health expert and Urology Times Editorial Council member says.

Metastatic castration-resistant prostate cancer patients whose tumors contain the androgen receptor (AR)-V7 splice variant are less likely to respond to enzalutamide (XTANDI) and abiraterone acetate (ZYTIGA), recent study results indicate.

Low testosterone is often blamed for a lower sex drive and potentially dangerous fat accumulation in men, however researchers from Massachusetts General Hospital report that a lack of estrogen is also to blame. Video provided by Renal & Urology News.